✉news WorldEU Politics first seen 3 h ago, last 3 h ago, peak #11
Hansoh lung cancer drug loses EU approval after AstraZeneca challenge
Original: Hansoh’s Tagrisso rival loses EU approval after AstraZeneca legal challenge
A copy of AstraZeneca's lung cancer drug Tagrisso developed by China's Hansoh Pharmaceutical has lost its European Union approval following a legal challenge mounted by AstraZeneca. The ruling removes the competing medicine from the EU market for now and hands the British drugmaker a win in its defence of Tagrisso's franchise, one of its biggest oncology products.
Why now: The EU decision is a notable win for AstraZeneca and a setback for Chinese drugmakers seeking to enter Western markets.
Hansoh PharmaceuticalAstraZenecaTagrissoEuropean Union
Evidence
- Hansoh’s Tagrisso rival loses EU approval after AstraZeneca legal challenge · fiercepharma.com
API: https://socialmediatrends-api.osmike.com/v1/trends/503879